Biomimetic Nanozymes in Small Molecule Drug Synthesis

Bionic nanozymes are nanoscale materials engineered to mimic enzymatic catalytic functions while retaining intrinsic nanomaterial properties. Their core features include:

• Enzyme-like catalytic activity: Achieve substrate conversion efficiency comparable to natural enzymes under physiological conditions, with some cases (e.g., MnO₂-Au nanozymes) showing 12x higher catalytic turnover rates than catalase.
• Multifunctionality: Integrate optical, magnetic, and electrochemical properties. For instance, Fe₃O₄ magnetic nanoparticles enable simultaneous H₂O₂ detection and magnetic separation.
• Extreme stability: Maintain >90% activity after 30 days in pH 3-11 or temperatures up to 80°C, outperforming natural enzymes that typically denature above 50°C.
• Designable specificity: Surface modifications (e.g., MOF-818(Cu) ligand engineering) allow selective targeting of substrates like glucose with 1.9 μM detection limits.

Traditional methods face three key limitations addressed by nanozymes:

• Multi-step inefficiency: Conventional routes require 6-12 synthesis/purification steps (e.g., paclitaxel synthesis), while nanozyme cascades can consolidate steps via ROS-mediated C-H activation.
• Chiral resolution waste: 40-50% material loss occurs in chiral separation; nanozymes like Fe-N/C single-atom catalysts achieve 99% enantioselectivity in asymmetric hydrogenation.

Scale-up challenges: Batch processes dominate traditional synthesis, whereas magnetic nanozymes enable continuous flow systems with 3x higher throughput.

Recent breakthroughs demonstrate:

• Cancer theranostics: MnO₂-Au nanozymes generate O₂ to reverse tumor hypoxia (60% ROS levels) while enabling photoacoustic imaging-guided radiotherapy.
• Environmental remediation: Co₃O₄/CeO₂ heterostructures degrade 95% organic pollutants in 30 mins via peroxidase-like Fenton reactions at neutral pH.
• Closed-loop drug synthesis: Self-assembled peptide nanozymes catalyze "synthesis → delivery → activation" cascades, achieving 80% tumor regression in murine models.

While promising, key challenges include:

• Precision control: Current methods struggle to replicate the Angstrom-scale active sites of cytochrome P450 enzymes for complex alkaloid synthesis.
• Batch consistency:<5% activity variation between nanozyme batches is required for GMP compliance, demanding improved synthetic protocols.
• In vivo safety: Long-term biodistribution studies show 15-30% hepatic accumulation of metal-based nanozymes, necessitating biodegradable alternatives.